An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A recent news item mentions semaglutide and tirzepatide — two drugs making headlines for weight loss — but the snippet provided doesn’t include details about a new study or regulatory change. So the basic news here is that these drugs are still appearing in media coverage in December 2025. I can explain what these medicines are, what past research has shown, why people care, and what to watch out for, but I can’t claim any new findings beyond the fact they’re in the news. Semaglutide is the active ingredient in medicines sold as Ozempic and Wegovy. It copies a natural gut hormone that helps control appetite. In practice that means it can make people feel less hungry and slow how quickly the stomach empties, so you eat less and feel full longer. Tirzepatide (sold as Zepbound or Mounjaro depending on the country and indication) acts on two related gut-hormone pathways at once — it mimics both GLP-1 and GIP hormones — which seems to boost effects on appetite and blood sugar compared with older drugs. What the research shows so far: large clinical trials in people with overweight or obesity found that both drugs produce substantial average weight loss when combined with lifestyle changes. Semaglutide trials showed average weight losses around 10–15% of body weight over several months in many participants; tirzepatide trials reported even larger average losses in some studies, sometimes 15–20% or more. These results come from controlled medical trials with hundreds to thousands of participants, not from anecdotes. Side-effect and safety data are also collected in those trials, but long-term real-world experience is still accumulating as more people use them. This matters because these medications have changed the conversation about medical weight loss. For people with obesity or certain weight-related health risks, they can be a powerful tool to reduce weight and improve conditions like type 2 diabetes and high blood pressure. Doctors and patients who have struggled to lose weight through diet and exercise alone are particularly interested. Employers, insurers, and health systems are also watching because wider use affects costs and care recommendations. There are important caveats. These drugs are prescription medicines with side effects that commonly include nausea, diarrhea, and sometimes more serious digestive issues. They require medical supervision, and stopping them often leads to weight regain unless other long-term strategies are in place. Not everyone can or should take them — people with certain medical histories, pregnant people, or those planning pregnancy are usually advised against them. Regulatory approvals and brand names differ by country, and cost and access remain major barriers for many people. Bottom line: semaglutide and tirzepatide are proven, prescription-weight-loss drugs that work well for many people, but they come with side effects, ongoing costs, and unanswered long-term questions; any decision to use them should be made with a healthcare provider.
Source: polskieradio.pl